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Introduction 
An estimated 20% of patients with CC do not 
respond to medical treatment and are said to 
have refractory chronic cough (RCC)1-2. Evidence 
suggests RCC is caused by hypersensitivity of 
sensory receptors in the airway epithelium known 
to regulate cough2. The primary sensory 
receptors are the transient receptor potential 
vanilloid (TRPV)3-7. These receptors can be found 
in the epithelial layer of the bronchus, larynx and 
nose3-5 and are very plastic. Behavioral cough 
suppression therapy (BCST) has been shown to 
result in reduced cough sensitivity7-9; however, 
the underlying mechanism that results in reduced 
cough sensitivity is unknown.  
VOICES (Voice Outcomes and Inquiry of Cough and Essentials in Swallowing) Lab 
Hypothesis 
BCST works by stimulating neuroplasticity that 
results in a reduction in TRPV expression in the 
airway epithelium of patients with RCC?  
Baseline Testing 
- Epiglottic biopsy 
-Urge-to-cough Test 
- Leicester cough 
questionnaire 
Analyze TRPV 
expression via 
Western blot1 
analysis 
Analyze TRPV 
mRNA expression 
via qPCR2 
Patient 
completes  3-4 
weeks of BCST 
Repeat steps 
post-BCST 
Specific Aim  
Quantify TRPV expression in human laryngeal 
epithelial cells (HLEC) pre and post BCST 
Methods 
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qPCR on HLEpC 
HLEpCRNA Isolation Protocol
RNA Area: 101.3431 Final Conc (ng/ul)
RNA Concentration:
(1:5 dilution) 61.85025 309.25
rRNA Ratio [28s / 18s]: 1.645794
RNA Integrity Number (RIN): 9.8 (B.02.08)
Result Flagging Color: 16768991
Result Flagging Label: RIN: 9.80
Total RNA isolation from HLEpCcells was performed using TRIzol™ 
reagent and assessed using the Bioanalyzer 2000.
Human laryngeal epithelial primary cells (HLEpC)
A. Human laryngeal epithelial primary cells (HLEpC) were grown 25 cm2 flasks (Corning) and 
maintained in BronchiaLifeTM Epithelial Airway Complete Medium (Lifeline Cell 
Technology) in a humidified atmosphere of 5 % CO2. 
B. Total RNA was isolated from HELC Cells (Lifeline Cell Technology, FC-0045) using TRIzol
Reagent (Thermo Fisher Scientific) according to manufacturers protocol.  The RNA 
Integrity Number (RIN) and concentration was confirmed using the Agilent Bioanalyzer 
2000 and spectrophotometric quantification respectively.  RNA met the following criteria: 
RIN>9.5, 260/280>1.8, 260/230> 1.8.
C. Bioanalyser 2000 results for HLEpCtotal RNA .
D. TRPV 1-5 qPCR -RNA samples and no reverse transcription controls were reverse 
transcribed using RT2 1st Strand Kit (Qiagen) in accordance with the manufacturers 
protocol.  Following reverse transcription, sample volume was adjusted to 100µl with 
nuclease free H2O.  5µl aliquot of each sample was used in subsequent qPCR reactions.  
RT2 qPCR Primer Assay (Qiagen, Frederick, MD). Efficiency for RT2 qPCR primers as 
reported by the manufacturer to be >90%. A seven step, 10-fold limiting serial dilution 
was performed to determine limits of detection. The 25 l qPCR reaction contained 1x 
Syber Green Mastermix (Qiagen) and gene specific primers at a final concentration of 
400nM each primer.   Real-time PCR reactions were performed on the Bio-Rad CFX96 for 
95°C for 10 min, 95°C for 15s, 60°C for 1 min, for 40 cycles, with fluorescence detection 
occurring after the annealing step.  Dissociation curve analysis was performed following 
the PCR reaction for 95°C 1min, 55°C 30s, 95°C 30s with detection occurring during the 
ramp step from 55°C to 95°C. 
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RT2 qPCR 
Primer Assay
Gene RefSeq
Number
PPH08086F TRPV1 NM_018727.5
PPH15769A TRPV2 NM_016113.4
PPH21337A TRPV3 NM_145068.3
PPH16107B TRPV4 NM_021625.4
PPH15903A TRPV5 NM_019841.6
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Green – TRPV1 
Blue – TRPV2 
Red – TRPV3 
Purple – TRPV4 
Laurie Slovarp, Ph.D., CCC-SLP, Sarjubhai Patel, Ph.D.,  
Jane Reynolds, M.S., CCC-SLP, Sarah Popp, B.A., B.S.  
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qPCR on Healthy HLEC 
Urge-to-Cough (UTC) test 
Results 
We are in the early stages of this study.  We’ve 
perfected qPCR on human laryngeal epithelial 
primary cells (HLEpC) and measured TRPV 
receptors on two healthy human biopsies (see 
below). Two patients with RCC are currently 
enrolled but have not yet been analyzed 
Epiglottic Biopsy 
1Western blot analysis is used to 
directly measure the presence of 
specific proteins in tissue samples 
 
2qPCR = quantitative polymerase 
chain reaction. Measures protein 
expression indirectly by measuring 
mRNA which precedes protein 
production 
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